Literature DB >> 9852243

Possible protective and pathogenic roles of gamma delta T lymphocytes in HIV-infections (Review).

F Poccia1, M Wallace, V Colizzi, M Malkovsky.   

Abstract

alpha beta and gamma delta T lymphocytes are largely responsible for the specificity of coordinated immune responses that are of crucial importance for protection from exogenous invaders and elimination of endogenous aberrations. One of the prominent distinguishing characteristics of primate gamma delta T lymphocytes is that most of their T cell receptors for antigen (gamma delta TCRs) are, unlike alpha beta TCRs, capable of recognizing nonpeptidic antigens in an MHC-unrestricted manner. Another interesting feature is that the gamma delta T cell subpopulation displays profound qualitative and quantitative changes in individuals with various infectious diseases. For example, the most frequent human peripheral blood gamma delta T cell subset expressing Vgamma9Vdelta2 TCRs is functionally disabled and numerically decreased in some HIV-infected persons. The nonresponsiveness of Vgamma9Vdelta2 T cells is accompanied by their decreased IFNç and TNFá production. The overall level of gamma T cell activation at different stages of HIV-infection may be clinically relevant. At an initial stage of HIV-infection, the extremely potent antiviral cytotoxic activities of Vgamma9Vdelta2 T cells may limit the viral spread. At later stages of disease, Vgamma9Vdelta2 T cell dysfunction may contribute to the loss of resistance to opportunistic pathogens (such as atypical mycobacteria) and neoplasms (e.g., lymphomas) frequently associated with HIV-infections. Also, it is possible that chronic stimulation of gamma delta T cells may result in immunopathology. In particular, the massive immunologic activation that appears to be the major contributing element of AIDS immunopathogenesis could be, at least in part, driven by gamma delta T cells overstimulated by repetitive exposures to HIV.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9852243     DOI: 10.3892/ijmm.1.2.409

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  7 in total

Review 1.  HIV infection: focus on the innate immune cells.

Authors:  Milena S Espíndola; Luana S Soares; Leonardo J Galvão-Lima; Fabiana A Zambuzi; Maira C Cacemiro; Verônica S Brauer; Fabiani G Frantz
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

2.  T cell receptor usage in patients with non-progressing HIV infection.

Authors:  M D Bodman-Smith; I Williams; R Johnstone; A Boylston; P M Lydyard; A Zumla
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

3.  gammadelta(+) T-Lp6phocyte cytotoxicity against envelope-expressing target cells is unique to the alymphocytic state of bovine leukemia virus infection in the natural host.

Authors:  P Lundberg; G A Splitter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  In vitro stimulation with a non-peptidic alkylphosphate expands cells expressing Vgamma2-Jgamma1.2/Vdelta2 T-cell receptors.

Authors:  P S Evans; P J Enders; C Yin; T J Ruckwardt; M Malkovsky; C D Pauza
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

5.  gammadelta T-cell anergy in human immunodeficiency virus-infected persons with opportunistic infections and recovery after highly active antiretroviral therapy.

Authors:  F Martini; R Urso; C Gioia; A De Felici; P Narciso; A Amendola; M G Paglia; V Colizzi; F Poccia
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

6.  Primary and Chronic HIV Infection Differently Modulates Mucosal Vδ1 and Vδ2 T-Cells Differentiation Profile and Effector Functions.

Authors:  Eleonora Cimini; Chiara Agrati; Gianpiero D'Offizi; Chrysoula Vlassi; Rita Casetti; Alessandra Sacchi; Raffaella Lionetti; Veronica Bordoni; Nicola Tumino; Paola Scognamiglio; Federico Martini
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

7.  Progression of a hepatosplenic gamma delta T-cell leukemia/lymphoma on hyperCVAD/MTX and ara-C: literature review and our institutional treatment approach.

Authors:  Abhijit Saste; Javier Arias-Stella; Philip Kuriakose
Journal:  Clin Case Rep       Date:  2015-11-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.